Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

Trial Profile

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Fatty liver; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms E-LIFT
  • Most Recent Events

    • 20 Mar 2018 Primary endpoint (Change in Liver Fat) has been met, according to results presented at The 100th Annual Meeting of the Endocrine Society.
    • 20 Mar 2018 Results (n=50) assessing effect of empagliflozin on liver fat in patients with type 2 diabetes and NAFLD, were presented at The 100th Annual Meeting of the Endocrine Society.
    • 13 Mar 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top